文献速递肝病消化道肿瘤与早癌

慢性丙型肝炎合并肝细胞癌患者直接抗病毒治疗的持续病毒学应答:系统评价与荟萃分析

Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
PubMed 文献 · J Hepatol · 2019-05-13

该系统评价与荟萃分析纳入49项研究、来自15个国家,包括3341例合并肝细胞癌(HCC)和35701例不合并HCC的慢性丙型肝炎患者,评估直接抗病毒药物(DAA)治疗的持续病毒学应答(SVR)。合并HCC患者总体SVR低于不合并HCC者(89.6% vs 93.3%,p=0.0012),活动性/残留HCC者SVR降低最明显(73.1% vs 92.6%,p=0.002)。

要点

  • 合并HCC患者DAA治疗的总体SVR低于不合并HCC者(89.6% vs 93.3%,p=0.0012)。
  • 活动性/残留HCC患者SVR降低幅度最大(73.1% vs 92.6%,p=0.002)。
  • 合并HCC且曾接受肝移植者SVR高于未移植者(p<0.001)。

核心结论

  • 合并HCC患者总体SVR低于不合并HCC者,尤其是活动性HCC者,但异质性高。
  • 需要继续努力积极筛查、诊断和治疗HCC,以确保更高的丙型肝炎治愈率。
  • 合并HCC患者更可能患有晚期肝病和降低治愈率的危险因素,因此需要更好控制的研究来证实这些发现。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、Embase、Web of Science和Cochrane Central Register of Controlled Trials,检索时间从2013年1月1日至2018年9月24日。
  • 纳入49项研究,来自15个国家,包括3341例合并HCC和35701例不合并HCC的患者。
  • 使用DerSimonian-Laird随机效应模型计算合并SVR率。

主要发现

  • 合并HCC患者总体合并SVR为89.6%(95% CI 86.8-92.1%,I²=79.1%),不合并HCC者为93.3%(95% CI 91.9-94.7%,I²=95.0%),p=0.0012。
  • 荟萃回归分析显示合并HCC与不合并HCC相比SVR降低4.8%(95% CI 0.2-7.4%)。
  • 活动性/残留HCC患者SVR为73.1%,非活动性/消融后HCC患者为92.6%,p=0.002,SVR降低18.8%。
  • 合并HCC且曾接受肝移植者SVR高于未接受肝移植者(p<0.001)。
  • 接受雷迪帕韦/索磷布韦治疗的合并HCC患者SVR为92.6%(n=884),不合并HCC者为97.8%(n=13141),p=0.026,异质性高(I²=84.7%,p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 异质性高(总体SVR分析I²=79.1%和95.0%;雷迪帕韦/索磷布韦亚组I²=84.7%)。
  • 合并HCC患者更可能患有晚期肝病和降低治愈率的危险因素,需要更好控制的研究来证实这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The effect of hepatocellular carcinoma (HCC) on the response to interferon-free direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C (CHC) infection remains unclear. Using a systematic review and meta-analysis approach, we aimed to investigate the effect of DAA therapy on sustained virologic response (SVR) among patients with CHC and either active, inactive or no HCC. METHODS: PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials were searched from 1/1/2013 to 9/24/2018. The pooled SVR rates were computed using DerSimonian-Laird random-effects models. RESULTS: We included 49 studies from 15 countries, comprised of 3,341 patients with HCC and 35,701 without HCC. Overall, the pooled SVR was lower in patients with HCC than in those without HCC (89.6%, 95% CI 86.8-92.1%, I2 = 79.1% vs. 93.3%, 95% CI 91.9-94.7%, I2 = 95.0%, p = 0.0012), translating to a 4.8% (95% CI 0.2-7.4%) SVR reduction by meta-regression analysis. The largest SVR reduction (18.8%) occurred in patients with active/residual HCC vs. inactive/ablated HCC (SVR 73.1% vs. 92.6%, p = 0.002). Meanwhile, patients with HCC who received a prior liver transplant had higher SVR rates than those who did not (p <0.001). Regarding specific DAA regimens, patients with HCC treated with ledipasvir/sofosbuvir had lower SVR rates than patients without HCC (92.6%, n = 884 vs. 97.8%, n = 13,141, p = 0.026), but heterogeneity was high (I2 = 84.7%, p <0.001). The SVR rate was similar in patients with/without HCC who were treated with ombitasvir/paritaprevir/ritonavir ± dasabuvir (n = 101) (97.2% vs. 94.8%, p = 0.79), or daclatasvir/asunaprevir (91.7% vs. 89.8%, p = 0.66). CONCLUSION: Overall, SVR rates were lower in patients with HCC, especially with active HCC, compared to those without HCC, though heterogeneity was high. Continued efforts are needed to aggressively screen, diagnose, and treat HCC to ensure higher CHC cure rates. LAY SUMMARY: There are now medications (direct-acting antivirals or "DAAs") that can "cure" hepatitis C virus, but patients with hepatitis C and liver cancer may be less likely to achieve cure than those without liver cancer. However, patients with liver cancer are also more likely to have advanced liver disease and risk factors that can decrease cure rates, so better controlled studies are needed to confirm these findings.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Ji F, Yeo YH, Wei MT, et al. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol. 2019. PMID: 31096005. doi:10.1016/j.jhep.2019.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。